机构名称：
¥ 1.0
表2。JAB-23425抑制KRAS突变/扩增的癌细胞的生长。A. JAB-23425 IC 50 data in KRAS-dependent cancer cell lines harboring multiple KRAS mutations, by pERK T202/Y204 HTRF assays (2 h) and CTG viability assay (6 days).ND, not detected.* 2D CTG生存力测定。B. JAB-23425 IC 50 data in KRAS WT cell lines with or without KRAS amplification, by pERK T202/Y204 HTRF assay (2 h) and CTG viability assay (6 days).Viability of cancer cell lines having KRAS WT amplification (KRAS-dependent) was significantly inhibited by JAB-23425, while there is no obvious inhibitory effect of JAB-23425 on cancer or normal cell lines without KRAS mutation or amplification (KRAS-independent).SK-MEL-2和KU-19-19 NRAS Q61R突变和A375 Harbors BRAF V600E突变。ND, not detected.* 2D CTG生存力测定。
抑制剂JAB-23425
主要关键词
相关文件推荐
![cinryze（C1酯酶抑制剂[人]）](/simg/d/d26132c5b11d8ba8bf7c7b98c5d2690aa90ede1f.webp)
